Selexis SA ("Selexis") announced today a strategic agreement with Zyngenia Inc. (Zyngenia) under which Selexis will utilize its' industry-leading SURE Cell Line Development Platform™ to generate production cell lines for Zyngenia's lead Zybody™ therapeutic programs.
"We are excited to support Zyngenia in the rapid advancement of their lead Zybody™ products," said Dr. Igor Fisch, CEO and co-founder of Selexis SA. "It's rare in today's biotech environment to find a truly innovative antibody platform such as Zyngenia's, where multiple disease targets can be addressed with a single protein therapy".
"We recognize the importance of incorporating industry-leading technologies in the development of our products and are pleased to be working with the experts at Selexis" adds David Hilbert, PhD, Head of Research and Development, Zyngenia, Inc. "Selexis' technological focus, aggressive development strategies, and commercial flexibility were important factors in our choice of providers in this area."
IFITM3 found to be critical regulator of immunotherapy sensitivity in small cell lung cancer